TIRP, a Novel Toll/Interleukin-1 receptor (TIR) Domain-containing Adapter Protein Involved in TIR Signaling*

Liang-Hua Bin {ddagger}, Liang-Guo Xu {ddagger} and Hong-Bing Shu {ddagger} § 

From the {ddagger}Department of Immunology, National Jewish Medical and Research Center, University of Colorado Health Sciences Center, Denver, Colorado 80206, and §Department of Cell Biology and Genetics, College of Life Sciences, Peking University, Beijing 100871, China

Received for publication, April 3, 2003 , and in revised form, April 22, 2003.


    ABSTRACT
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
The Toll/interleukin-1 receptor (TIR) family members play important roles in host defense. These receptors signal through TIR domain-containing adapter proteins. In this report, we identified a novel TIR domain-containing adapter protein designated as TIRP. Co-immunoprecipitation experiments suggest that TIRP is associated with IL-1 receptors. TIRP also interacts with kinase-inactive mutants of IRAK and IRAK-4, IRAK-2, IRAK-M, and TRAF6. Overexpression of TIRP activates NF-{kappa}B and potentiates IL-1 receptor-mediated NF-{kappa}B activation. A dominant negative mutant of TIRP inhibits IL-1- but not tumor necrosis factor-triggered NF-{kappa}B activation. Moreover, TIRP-mediated NF-{kappa}B activation is inhibited by dominant negative mutants of IRAK, IRAK-2, TRAF6, and IKK{beta}. Our findings suggest that TIRP is involved in IL-1-triggered NF-{kappa}B activation and functions upstream of IRAK, IRAK-2, TRAF6, and IKK{beta}


    INTRODUCTION
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
The Toll/interleukin-1 receptor (TIR)1 family members are evolutionary conserved proteins that are critically involved in host defense from plants to humans (15). The TIR family is divided into two subfamilies, the IL-1 receptor (IL-1R) and Toll-like receptor (TLR) subfamilies. In mammals, the IL-1R subfamily members are important mediators of inflammation and adaptive immune responses, whereas the TLR subfamily members recognize microbial products termed PAMPs (pathogen-associated molecular patterns) and are critical components of the innate immune system (15).

The IL-1R and TLR subfamilies are distinguished through structural divergence in the extracellular domains. The IL-1R subfamily members contain immunoglobulin-like motifs, whereas the TLR subfamily members contain leucine-rich repeats. However, both subfamily members share a conserved cytoplasmic domain, the TIR domain (15). Various studies have shown that the TIR domain is required for TIR family member-mediated signaling that leads to activation of transcription factors NF-{kappa}B, activating protein-1, and ATF-2 and subsequent induction of various chemokines and cytokines that are involved in host defense against the pathogens (15).

The signaling pathways initiated by IL-1 receptors have become a paradigm on how other TIR family receptors signal. Upon IL-1 stimulation, IL-1R1 forms a complex with IL-1RAcP, a co-receptor (69). This leads to recruitment of the adapter protein MyD88 to the receptor signaling complex (1012). MyD88, in turn, recruits the serine/threonine kinase IRAK (11). Once IRAK is recruited to the receptor complex, it is activated and then dissociated from the receptor complex (13). Dissociated IRAK interacts with TRAF6, which then activates NF-{kappa}B through a kinase cascade containing TAK1 and IKK (1316).

In addition to IL-1 receptor signaling, MyD88 is also involved in signaling by TLRs (15). Gene knock-out studies have suggested that MyD88 is required for cytokine induction triggered by a variety of ligands that signal through the TIR family members, such as IL-1{beta}, IL-18, lipopolysaccharide, MALP-2, CpG-DNA, and poly(I·C) (17). However, it has been shown that poly(I·C) and lipopolysaccharide-induced NF-{kappa}B and JNK activation was delayed but not abolished in MyD88–/– cells. In addition, poly(I·C) and lipopolysaccharide still triggered dendritic cell maturation (17). These studies suggest that MyD88-independent pathways exist. Recently, two additional TIR domain-containing adapter molecules, TIRAP/Mal and TRIF/TICAM, were identified (1821). TIRAP is associated with TLR4. A dominant negative mutant of TIRAP inhibits NF-{kappa}B activation triggered by TLR4 but not by TLR9 or IL-1R (18, 19). Furthermore, gene knock-out studies have indicated that TIRAP is essential for lipopolysaccharide-induced cytokine production, suggesting that TIRAP is required for TLR4 signaling (22, 23). It has also been shown that TIRAP is involved in signaling triggered by ligands for TLR1, TRL2, and TLR6, but not by IL-1 and IL-18, and ligands for TLR3, TLR7, and TLR9 (22, 23).

TRIF is the third identified TIR domain-containing adapter molecule. In addition to NF-{kappa}B, TRIF also activates IFN-{beta} promoter (20, 21). A dominant negative mutant of TRIF inhibits TLR2, TLR3, TLR4, and TLR7-mediated NF-{kappa}B activation and TLR3-mediated activation of IFN-{beta} promoter (20, 21). So far, TRIF is the only TIR-containing adapter protein that is implied in TLR3-mediated production of IFN-{beta}, suggesting that TRIF is involved in TLR3-activating NF-{kappa}B as well as IFN-{beta} (20, 21).

Similar with the TIR domain-containing adapter proteins, four IRAK-like molecules have been identified (24). Although IRAK was firstly identified as a component of the IL-1R signaling complex and later shown to be recruited to the TLR signaling complexes upon ligand stimulation, gene knock-out studies have indicated that IRAK deficiency has a relatively mild effect on IL-1R and TLR signaling (25, 26). It has been shown that the kinase activity of IRAK is dispensable for IRAK function as a mediator of TIR-triggered NF-{kappa}B activation (27). IRAK-2 and IRAK-M, two other members of the IRAK family, have no kinase activity but activate NF-{kappa}B when overexpressed in 293 cells and partially restore IL-1 signaling in IRAK–/– cells (10, 28, 29).

IRAK-4, the fourth member of the IRAK family, has unique features that distinguish it from all of the other IRAK proteins. First, overexpression of IRAK-4 does not result in robust NF-{kappa}B activation. Second, expression of a kinase-inactive mutant of IRAK-4 is sufficient to inhibit IL-1-mediated NF-{kappa}B activation in cells (30). By contrast, corresponding point mutations of IRAK, IRAK-2, or IRAK-M do not have the same dominant negative effects (10, 28, 31). Third, IRAK is a direct substrate of IRAK-4, but IRAK-4 can not be phosphorylated by IRAK (30). Finally, gene knock-out studies indicate that IRAK-4 is required for signaling triggered by IL-1R and TLR engagement (32). These results suggest that IRAK-4, as well as its kinase activity, is required for TIR signaling and that IRAK-4 functions upstream of IRAK.

Recently, it has been shown that IRAK-M prevents dissociation of IRAK and IRAK-4 from MyD88 and formation of IRAK·TRAF6 complexes (28). IRAK-M–/– cells exhibited increased cytokine production upon TLR/IL-1 stimulation and bacterial challenge. IRAK-M–/– mice showed increased inflammatory responses to bacterial infection and decreased tolerance to endotoxin shock (28). These data suggest that IRAK-M is a negative regulator of signaling by the TIR family members.

In this study, we identified a novel TIR domain-containing adapter protein, designated as TIRP (for TIR-containing protein). Our findings suggest that TIRP interacts with various proteins involved in the TIR signaling pathways and plays a role in NF-{kappa}B activation triggered by the IL-1 receptors.


    EXPERIMENTAL PROCEDURES
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Reagents—Recombinant TNF-{alpha} and IL-1 (R&D Systems, Minneapolis, MN), monoclonal antibodies against FLAG, and the HA (Sigma) epitopes were purchased from the indicated resources.

Northern Blot Hybridization—Human multiple tissue mRNA blots were purchased from Clontech (Palo Alto, CA). The blots were hybridized with [32P]dCTP and [32P]dATP-labeled cDNA probe corresponding to TIRP coding sequence. The hybridization was performed in the rapid hybridization buffer (Clontech) under high stringency condition.

Constructs—NF-{kappa}B luciferase reporter construct (Dr. Gary Johnson, University of Colorado Health Sciences Center) and mammalian expression plasmids for FLAG-TRAF6, FLAG-TRAF6-(289–522), IKK{beta}, I{kappa}B{alpha}(SS/AA) (Dr. David Goeddel, Tularik Inc.), FLAG-IRAK, FLAG-IRAK-(K239S), FLAG-IRAK-4, FLAG-IRAK-4-KA, FLAG-IRAK-4-(1–191), FLAG-IRAK-M, FLAG-IL-1R1, FLAG-IL-1RAcP, Myc-MyD88 (Dr. Zhaodan Cao, Tularik Inc.), pCMV1-FLAG-TLR2, and pCMV1-FLAG-TLR4 (Dr. Bruce Beutler, Scripps Research Institute) were provided by the indicated investigators. Mammalian expression plasmids for HA-TIRP and its deletion mutants, FLAG-tagged IRAK-2, IRAK-(1–215), IRAK-2-(97–590), TRIF, and TIRAP, were constructed by PCR amplification of the corresponding cDNA fragments and subsequent cloning into a CMV promoter-based vector containing a 5'-HA or FLAG tag. IFN-{beta} luciferase reporter was constructed by PCR amplification of the human IFN-{beta} promoter fragment (–300 to + 25) and cloning into pGL3-Basic vector (Promega, Madison, WI).

Cell Transfection and Reporter Gene Assays—293 cells (2 x 105) were seeded in 6-well dishes and transfected the following day by the standard calcium phosphate precipitation (33). Within the same experiment, each transfection was performed in triplicate, and where necessary, empty control plasmid was added to ensure that each transfection receives the same amount of total DNA. To normalize for transfection efficiency, 0.2 µg of RSV-{beta}-galactosidase luciferase reporter plasmid was added to each transfection.

Approximately sixteen hours after transfection, luciferase reporter assays were performed using a luciferase assay kit (BD Biosciences) by following the manufacturer's protocol. {beta}-Galactosidase activity was measured using the Galacto-Light chemiluminescent kit (TROPIX, Bedford, MA). Luciferase activities were normalized on the basis of {beta}-galactosidase luciferase expression levels. All of the reporter gene assays were repeated for at least three times. Data shown were from one representative experiment

Co-immunoprecipitation and Western Blot Analysis—For transient transfection and co-immunoprecipitation experiments, 293 cells (2 x 106) were transfected for 24 h. Transfected cells were lysed in 1 ml of lysis buffer (15 mM Tris, 120 mM NaCl, 1% Triton X-100, 25 mM KCl, 2 mM EGTA, 2 mM EDTA, 0.1 mM dithiothreitol, 0.5% Triton X-100, 10 µg/ml leupeptin, 0.5 mM phenylmethylsulfonyl fluoride, pH 7.5). For each immunoprecipitation, a 0.4-ml aliquot of lysate was incubated with 0.5 µg of the indicated monoclonal antibody or control mouse IgG and 25 µl of a 1:1 slurry of GammaBind G Plus-Sepharose (Amersham Biosciences) for 2 h. The Sepharose beads were washed three times with 1 ml of lysis buffer with 500 mM NaCl. The precipitates were fractionated on SDS-PAGE, and subsequent Western blot analysis was performed as described. All of the immunoprecipitation experiments were repeated for at least three times, and similar data were obtained.


    RESULTS
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Identification and Cloning of TIRP—It has been suggested that several TIR domain-containing adapters are involved in the TIR signaling pathways and that differential use of these adapters provides the specificity in the TIR signaling pathways (15). We reasoned that additional TIR domain-containing adapters might exist. Therefore, we searched the GenBankTM EST databases for sequences that encode TIR domain-containing proteins. This effort identified multiple human EST clones that encode a protein designated as TIRP. GenBankTM accession number for the longest EST clone is BQ438847 [GenBank] . Further BLAST searches also identified mouse ortholog of human TIRP. Sequence comparisons suggest that human and mouse TIRPs share ~70% identity at amino acid level (Fig. 1A). TIRP contains a TIR domain at the middle, which is mostly conserved with that of TRIF/TICAM (Fig. 1B) (1821).



View larger version (67K):
[in this window]
[in a new window]
 
FIG. 1.
Identification and tissue expression of TIRP. A, alignment of amino acid sequences of human and mouse TIRPs. The putative TIR domain is underlined. hTIRP, human TIRP; mTIRP, mouse TIRP. The GenBankTM accession numbers for human and mouse TIRP are AY275836 and AY275837, respectively. B, alignment of the TIR domain of human TIRP with that of human TRIF and the smart0025 TIR domain from the National Center for Biotechnology Information. C, tissue distribution of human TIRP mRNA. Human multiple tissue blots were hybridized with a cDNA probe corresponding to human TIRP coding sequence. PBL, peripheral blood leukocyte.

 

Northern blot analysis suggests that human TIRP mRNA is expressed in most examined tissues including the spleen, prostate, testis, uterus, small intestine, colon, peripheral blood leukocytes, heart, placenta, lung, liver, skeletal muscle, and pancreas (Fig. 1C). Three transcripts of different sizes, ~3.8, 3.6, and 2.0 kb, respectively, were detected, and these transcripts were differentially expressed in the tissues (Fig. 1C).

TIRP Interacts with IL-1R1 and IL-1RAcP—Previously, it has been shown that the TIR domain-containing adapter proteins interact with TIR receptors (15). We determined whether TIRP interacts with IL-1R1, IL-1RAcP, and TLR2. To do this, we transfected expression plasmids for C-terminal FLAG-tagged receptors and N-terminal HA-tagged TIRP into 293 cells. Co-immunoprecipitation experiments indicated that TIRP interacted with IL-1R1 and IL-1RAcP but not with TLR2 and TLR4 (Fig. 2A). These data suggest that TIRP is a component of the IL-1 receptor signaling complex.



View larger version (63K):
[in this window]
[in a new window]
 
FIG. 2.
TIRP interacts with IL-1R1, IL-1RAcP, TRIF, and TIRAP. A, TIRP is associated with IL-1R1 and IL-1RAcP but not with TLR2 and TLR4. B, TIRP interacts with TRIF and TIRAP. 293 cells were transfected with expression plasmids for HA-tagged TIRP and the indicated FLAG ({alpha}-F) tagged proteins. Cell lysates were immunoprecipitated with anti-FLAG antibody or control IgG. The immunoprecipitates were analyzed by Western blots (WB) with anti-HA antibody. The expression levels of all of the proteins were comparable as suggested by Western blot analysis of the lysates (data not shown).

 

TIRP Interacts with Other TIR-containing Adapter Proteins—It has been reported that TIR-containing adapter proteins can form heterodimers (15). To test whether TIRP can interact with known TIR-containing adapter proteins, we transfected expression plasmids for TIRP and MyD88, TIRAP, and TRIF into 293 cells, respectively. Co-immunoprecipitation experiments suggest that TIRP interacts with TIRAP and TRIF (Fig. 2B) but not with MyD88 (data not shown). These data suggest that TIRP selectively interacts with other TIR-containing adapter proteins.

TIRP Interacts with IRAKs—MyD88, TIRAP, and TRIF function as adapters to recruit IRAKs into the signaling complexes of TIR family members (1013, 2023). We examined whether TIRP also interacts with IRAKs. In transient transfection and co-immunoprecipitation experiments, TIRP did not interact with wild-type IRAK and IRAK-4 but interacted with kinase-inactive mutants of IRAK and IRAK-4 (Fig. 3A). These results are similar to MyD88, which has been shown to interact with kinase-inactive mutant but not with wild type IRAK.



View larger version (67K):
[in this window]
[in a new window]
 
FIG. 3.
TIRP interacts with kinase-inactive (KA) IRAKs and TRAF6. A, TIRP interacts with kinase-inactive IRAK and IRAK-4, IRAK-2, and IRAK-M. 293 cells (2 x 106) were transfected with expression plasmids for HA-tagged TIRP and FLAG-tagged IRAK, IRAK, IRAK-KA, IRAK-4, IRAK-4-KA, IRAK-2, and IRAK-M. Cell lysates were immunoprecipitated with anti-FLAG ({alpha}-F) or control IgG. The immunoprecipitates were analyzed by Western blots (WB) with anti-HA antibody. B, TIRP interacts with TRAF6 and its TRAF domain but not with TRAF5. 293 cells (2 x 106) were transfected with expression plasmids for HA-tagged TIRP and FLAG ({alpha}-F) tagged TRAF5, TRAF6, and TRAF6-(289–595). Cell lysates were immunoprecipitated with anti-FLAG or control IgG. The immunoprecipitates were analyzed by Western blots with anti-HA antibody. C, TRAF6 interacts with the TIR domain of TIRP. 293 cells (2 x 106) were transfected with expression plasmids for FLAG-TRAF6 and various HA-tagged TIRP mutants. Cell lysates were immunoprecipitated with anti-HA or control IgG. The immunoprecipitates were analyzed by Western blots with anti-FLAG antibody. The expression levels of all of the proteins were comparable as suggested by Western blot analysis of the lysates (data not shown). aa, amino acid.

 

In transient transfection and co-immunoprecipitation experiments, TIRP also interacted with wild-type IRAK-2 and IRAK-M (Fig. 3A), two IRAK family members that have no kinase activity. Taken together, these data suggest that TIRP only interacts with kinase-inactive IRAKs.

TIRP Interacts with TRAF6 —It has been shown that TRAF6 is associated with activated IRAK (13). We examined whether TIRP is associated with TRAF6. To do this, we transfected FLAG-tagged TRAF6 and HA-tagged TIRP into 293 cells and performed co-immunoprecipitation experiments. These experiments indicated that TIRP interacted with TRAF6 but not with TRAF5 (Fig. 3B). Also, the TRAF domain of TRAF6 was sufficient for its interaction with TIRP (Fig. 3B). These results suggest that TIRP specifically interacts with TRAF6.

We next determined which domain of TIRP is responsible for its interaction with TRAF6. TIRP contains a conserved TIR domain at the middle flanked by unconserved N- and C-terminal domains. We made HA-tagged TIRP deletion mutants containing one individual domain or combinations of different domains. Transient transfection and co-immunoprecipitation experiments suggest that the TIR domain is required and sufficient for the interaction of TIRP with TRAF6 (Fig. 3C). Interestingly, we found that the TIR domain of TIRP contains a PRERT motif at amino acid 181, which is conserved with the defined TRAF6 binding motif PXEXX (34).

Overexpression of TIRP Activates NF-{kappa}B but Not IFN-{beta} Promoter—Since TIRP interacts with proteins involved in signaling by TIR family members, we determined whether TIRP activates NF-{kappa}B. We transfected a mammalian expression plasmid for TIRP into 293 cells and performed NF-{kappa}B luciferase reporter gene assays. These experiments indicated that TIRP could activate NF-{kappa}B (Fig. 4A). However, TIRP activated NF-{kappa}B to a lesser degree than MyD88, TRIF, and TIRAP in the same experiments (Fig. 4A).



View larger version (14K):
[in this window]
[in a new window]
 
FIG. 4.
TIRP activates NF-{kappa}B and potentiates IL-1 receptor-mediated NF-{kappa}B activation. A, activation of NF-{kappa}B by TIRP and other TIR-containing adapter proteins. 293 cells (2 x 105) were transfected with 0.3 µg of NF-{kappa}B-luciferase reporter plasmid, 0.2 µg of RSV-{beta}-galactosidase plasmid, and 1 µg of an expression plasmid for TIRP, MyD88, TRIF, or TIRAP. Sixteen hours after transfection, luciferase and {beta}-galactosidase reporter assays were performed. Data shown are average luciferase activities normalized by {beta}-galactosidase activities. B, TIRP does not activate IFN-{beta} promoter. The experiments were done as in A with the exception that the NF-{kappa}B-luciferase reporter plasmid was replaced with IFN-{beta} promoter luciferase reporter plasmid. C, TIRP potentiates IL-1 receptor-mediated NF-{kappa}B activation. 293 cells (2 x 105) were transfected with 0.3 µg of NF-{kappa}B-luciferase reporter plasmid, 0.2 µg of RSV-{beta}-galactosidase, 1 µg of an expression plasmid for TIRP, and 1 µg of an expression plasmid for IL-1R1 or IL-1RAcP. Reporter gene assays were performed as in A.

 

Previously, it has been shown that TRIF can potently activate IFN-{beta} promoter. To examine whether TIRP can activate IFN-{beta} promoter, we transfected 293 cells (2 x 105) with various amounts of TIRP plasmid ranging from 0.01 to 3.2 µg and then performed IFN-{beta} luciferase reporter gene assays. The result indicated that TIRP could not activate IFN-{beta} promoter regardless of the transfected TIRP plasmid concentration (Fig. 4B) (data not shown). In these experiments, MyD88 and TIRAP also did not activate IFN-{beta} promoter, whereas TRIF potently activated IFN-{beta} promoter (Fig. 4B).

Because TIRP can weakly activate NF-{kappa}B, we determined whether it potentiates IL-1R1- and IL-1AcP-mediated NF-{kappa}B activation. Previously, it has been shown that the overexpression of IL-1R1 or IL-1RAcP alone weakly activates NF-{kappa}B. In reporter gene assays, we found that TIRP could synergy with IL-1R1 or IL-1-RAcP to activate NF-{kappa}B (Fig. 4C).

A TIRP Dominant Negative Mutant Inhibits NF-{kappa}B Activation Mediated by IL-1 Receptors but Not by TRAF6 and IKK{beta} Previously, it has been shown that the TIR domains of MyD88, TRIF, and TIRAP function as dominant negative mutants to inhibit signaling by the TIR family members (1013, 2023). We examined whether the TIR domain of TIRP can inhibit NF-{kappa}B activation triggered by IL-1 receptors. In reporter gene assays, we found that the TIR domain of TIRP, TIRP-(78–171), significantly inhibited NF-{kappa}B activation mediated by overexpression of IL-1R1 and IL-1RacP but not by overexpression of TRAF6 and IKK{beta} (Fig. 5A). In these experiments, TIRP-(78–171) did not inhibit TLR4 and only slightly inhibited TLR2-mediated NF-{kappa}B activation (Fig. 5A).



View larger version (17K):
[in this window]
[in a new window]
 
FIG. 5.
Functional roles of TIRP in IL-1-induced NF-{kappa}B activation pathways. A, effects of TIRP dominant negative mutant on NF-{kappa}B activation induced by overexpression of IL-1 receptors, TRAF6, IKK{beta}, TLR2, and TLR4. 293 cells (2 x 105) were transfected with 0.3 µg of NF-{kappa}B-luciferase reporter plasmid, 0.2 µg of RSV-{beta}-galactosidase plasmid, and 1 µg of the indicated expression plasmids in the absence (open bars) or presence (solid bars) of 1 µg of expression plasmid for TIRP-(78–171). Sixteen hours after transfection, luciferase and {beta}-galactosidase reporter assays were performed. Data shown are average luciferase activities normalized by {beta}-galactosidase activities. B, effects of TIRP dominant negative mutant on NF-{kappa}B activation induced by IL-1 and TNF. 293 cells (2 x 105) were transfected with 0.3 µg of NF-{kappa}B-luciferase reporter plasmid, 0.2 µg of RSV-{beta}-galactosidase plasmid, 1 µg of expression plasmid for TIRP-(78–171) (solid bars), or empty control plasmid (open bars). Fourteen hours after transfection, the cells were treated with IL-1 (20 ng/ml) and TNF (20 ng/ml) or left untreated for six hours. Reporter gene assays were performed as in A. C, effects of various mutants on TIRP-mediated NF-{kappa}B activation. 293 cells (2 x 105) were transfected with 0.3 µg of NF-{kappa}B-luciferase reporter plasmid, 0.2 µg of RSV-{beta}-galactosidase plasmid, 1 µg of an expression plasmid for TIRP, and 1 µg of the indicated plasmids. Sixteen hours after transfection, reporter gene assays were performed as in A.

 

In reporter gene assays, TIRP-(78–171) also inhibited NF-{kappa}B activation triggered by IL-1 but not by TNF (Fig. 5B). These data suggest that TIRP is specifically involved in IL-1-triggered NF-{kappa}B activation.

NF-{kappa}B Activation by TIRP Is Inhibited by Dominant Negative Mutants of IRAK, IRAK-2, TRAF6, and IKK{beta}To determine the molecular order of TIRP in the IL-1 signaling pathways, we determined whether TIRP-mediated NF-{kappa}B activation is inhibited by dominant negative mutants of proteins involved in IL-1 signaling pathways. In reporter gene assays, we found that dominant negative mutants of IRAK, IRAK-2, TRAF6, and IKK{beta} as well as I{kappa}B{alpha}-undegradable mutant potently inhibited TIRP-induced NF-{kappa}B activation (Fig. 5C). In these experiments, dominant negative mutants of MyD88 and IRAK-4 did not inhibit TIRP-mediated NF-{kappa}B activation (Fig. 5C). These data suggest that TIRP functions upstream of IRAK, IRAK-2, TRAF6, and IKK{beta} in IL-1 receptor-mediated NF-{kappa}B activation pathways.


    DISCUSSION
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Previously, three TIR-containing adapter proteins have been reported, including MyD88, TIRAP/Mal, and TRIF/TICAM. In this paper, we describe the identification of TIRP, the fourth member of this family.

TIRP shares many similar properties with the other three TIR-containing adapter proteins. It contains a conserved TIR domain and is associated with IL-1RI and IL-1RAcP, suggesting that TIRP plays a role in IL-1 signaling.

Previous studies have shown that MyD interacts with kinase-inactive mutant of IRAK but not wild-type IRAK. It has been proposed that MyD88 recruits inactive IRAK to IL-1R complex. Once IRAK is activated in the complex, it dissociates with MyD88 and then interacts with TRAF6 (1012). Similar to MyD88, TIRP interacts with kinase-inactive mutants of IRAK and IRAK-4 but not with their wild-type counterparts. These data suggest that TIRP may also interact with inactive IRAK and IRAK-4 in cells and dissociate when they are activated.

In addition to kinase-inactive IRAK and IRAK-4 mutants, TIRP also interacts with IRAK-2 and IRAK-M, two IRAK family members that are kinase-inactive. These data further support our hypothesis that TIRP interacts with kinase-inactive IRAKs.

In addition to IRAKs, TIRP also interacts with TRAF6. This interaction is mediated by the TRAF domain of TRAF6. TIRP does not interact with TRAF5, a TRAF family member that is involved in signaling by TNF receptor family members. The TIR domain of TIRP is required and sufficient for its interaction with TRAF6. These data suggest that TIRP specifically interacts with TRAF6 and other signaling proteins involved in IL-1 signaling pathways.

Overexpression of TIRP activates NF-{kappa}B but not IFN-{beta} promoter. A dominant negative mutant of TIRP (TIRP-(78–171)) inhibits IL-1-induced but not TNF-induced NF-{kappa}B activation. Conversely, dominant negative mutants of IRAK, IRAK-2, TRAF6, and IKK{beta} inhibited TIRP-mediated NF-{kappa}B activation. These data suggest that TIRP functions upstream of IRAK, IRAK-2, TRAF6, and IKK{beta} in the IL-1-induced NF-{kappa}B activation pathway. Because IL-1 is unable to activate NF-{kappa}B in certain MyD88-deficient cells, it is possible that these cells do not express TIRP. Alternatively, TIRP is not able to complement MyD88 deficiency and both proteins are required for IL-1-induced NF-{kappa}B activation.

Although TIRP interacts with kinase-inactive mutant of IRAK-4, a dominant negative mutant of IRAK-4 did not inhibit TIRP-induced NF-{kappa}B activation. It is possible that IRAK-4 functions upstream of TIRP in IL-1 signaling.

In conclusion, we identified TIRP, a novel TIR domain-containing adapter protein that is involved in IL-1-triggered NF-{kappa}B activation pathways. It should be pointed out that our characterization of TIRP was based on the mammalian overexpression systems. Further experiments, such as analysis of TIRP knock-out mice, will be needed to confirm a role of TIRP in IL-1 or other TIR signaling pathways.


    FOOTNOTES
 
* This work was supported in part by the National Institutes of Health (Grant AI49992), the Ellison Medical Foundation, the National Natural Science Foundation of China (Grants 39925016 and 30100097), the Chinese High Technology Program (Grant 2001AA221281), and the Special Funds for Major State Basic Research of China (Grant G19990 [GenBank] 539) (to H.-B. S.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Back

To whom correspondence should be addressed: National Jewish Medical and Research Center, 1400 Jackson St., k516c, Denver, CO 80206. Tel.: 303-398-1329; Fax: 303-398-1396; E-mail: shuh{at}njc.org.

1 The abbreviations used are: TIR, Toll/interleukin-1 receptor; TIRP, TIR domain-containing protein; TLR, Toll-like receptor; IRAK, interleukin-1 receptor-associated kinase; TRIF, TIR domain-containing adapter-inducing IFN-{beta}; JNK, c-Jun NH2-terminal kinase; TNF, tumor necrosis factor; TRAF, TNF receptor-associated factor; IKK, I{kappa}B kinase; IFN, interferon; HA, hemagglutinin; CMV, cytomegalovirus; RSV, Rous sarcoma virus; AcP, accessary protein; TIRAP, TIR domain-containing adapter protein; MAL, MyD88-adapter-like. Back


    ACKNOWLEDGMENTS
 
We thank Drs. David Goeddel, Zhaodan Cao, Gary Johnson, and Bruce Beutler for reagents.



    REFERENCES
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Janeway, C. A., Jr., and Medzhitov, R. (2002) Annu. Rev. Immunol. 20, 197–216[CrossRef][Medline] [Order article via Infotrieve]
  2. Martin, M. U., and Wesche, H. (2002) Biochim. Biophys. Acta 1592, 265–280[CrossRef][Medline] [Order article via Infotrieve]
  3. O'Neill, L. A. (2002) Curr. Top. Microbiol. Immunol. 270, 47–61[Medline] [Order article via Infotrieve]
  4. Akira, S., Takeda, K., and Kaisho, T. (2001) Nature Immunol. 2, 675–680[CrossRef][Medline] [Order article via Infotrieve]
  5. Aderem, A., and Ulevitch, R. J. (2000) Nature 406, 782–787[CrossRef][Medline] [Order article via Infotrieve]
  6. Greenfeder, S. A., Nunes, P., Kwee, L., Labow, M., Chizzonite, R. A., and Ju, G. (1995) J. Biol. Chem. 270, 13757–13765[Abstract/Free Full Text]
  7. Wesche, H., Korherr, C., Kracht, M., Falk, W., Resch, K., and Martin, M. U. (1997) J. Biol. Chem. 272, 7727–7731[Abstract/Free Full Text]
  8. Huang, J., Gao, X., Li, S., and Cao, Z. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 12829–12832[Abstract/Free Full Text]
  9. Cullinan, E. B., Kwee, L., Nunes, P., Shuster, D. J., Ju, G., McIntyre, K. W., Chizzonite, R. A., and Labow, M. A. (1998) J. Immunol. 161, 5614–5620[Abstract/Free Full Text]
  10. Muzio, M., Ni, J., Feng, P., and Dixit, V. M. (1997) Science 278, 1612–1615[Abstract/Free Full Text]
  11. Wesche, H., Henzel, W. J., Shillinglaw, W., Li, S., and Cao, Z. (1997) Immunity 7, 837–847[Medline] [Order article via Infotrieve]
  12. Burns, K., Martinon, F., Esslinger, C., Pahl, H., Schneider, P., Bodmer, J. L., DiMarco, F., French, L., and Tschopp, J. (1998) J. Biol. Chem. 273, 12203–12209[Abstract/Free Full Text]
  13. Cao, Z., Yiong, J., Takeuchi, M., Kurama, T., and Goeddel, D. (1996) Nature 383, 443–446[CrossRef][Medline] [Order article via Infotrieve]
  14. Takaesu, G., Kishida, S., Hiyama, A., Yamaguchi, K., Shibuya, H., Irie, K., Ninomiya-Tsuji, J., and Matsumoto, K. (2000) Mol. Cell 5, 649–658[Medline] [Order article via Infotrieve]
  15. Takesu, G., Ninomiya-Tsuji, J., Kishida, S., Li, X., Stark, G. R., and Matsumoto, K. (2001) Mol. Cell. Biol. 7, 2475–2484[CrossRef]
  16. Ninomiya-Tsuji, J., Kishimoto, K., Hiyama, A., Inoue, J., Cao, Z., and Matsumoto, K. (1999) Nature 398, 252–256[CrossRef][Medline] [Order article via Infotrieve]
  17. Adachi, O., Kawai, T., Takeda, K., Matsumoto, M., Tsutsui, H., Sakagami, M., Nakanishi, K., and Akira, S. (1998) Immunity 9, 143–150[Medline] [Order article via Infotrieve]
  18. Horng, T., Barton, G., and Medzhitov, R. (2001) Nature Immunol. 2, 835–841[CrossRef][Medline] [Order article via Infotrieve]
  19. Fitzgerald, K. A., Palsson-McDermott, E. M., Bowie, A. G., Jefferies, C. A., Mansell, A. S., Brady, G., Brint, E., Dunne, A., Gray, P., Harte, M. T., McMurray, D., Smith, D. E., Sims, J. E., Bird, T. A., and O'Neill, L. A. (2001) Nature 413, 78–83[CrossRef][Medline] [Order article via Infotrieve]
  20. Yamamoto, M., Sato, S., Mori, K., Hoshino, K., Takeuchi, O., Takeda, K., and Akira, S. (2002) J. Immunol. 169, 6668–6672[Abstract/Free Full Text]
  21. Oshiumi, H., Matsumoto, M., Funami, K., Akazawa, T., and Seya, T. (2003) Nature Immunol. 4, 161–167[CrossRef][Medline] [Order article via Infotrieve]
  22. Horng, T., Barton, G. M., Flavell, R. A., and Medzhitov, R. (2002) Nature 420, 329–333[CrossRef][Medline] [Order article via Infotrieve]
  23. Yamamoto, M., Sato, S., Hemmi, H., Sanjo, H., Uematsu, S., Kaisho, T., Hoshino, K., Takeuchi, O., Kobayashi, M., Fujita, T., Takeda, K., and Akira, S. (2002) Nature 420, 324–329[CrossRef][Medline] [Order article via Infotrieve]
  24. Suzuki, N., Suzuki, S., and Yeh, W. C. (2002) Trends Immunol. 23, 503–506[CrossRef][Medline] [Order article via Infotrieve]
  25. Thomas, J. A., Allen, J. L., Tsen, M., Dubnicoff, T., Danao, J., Liao, X. C., Cao, Z., and Wasserman, S. A. (1999) J. Immunol. 163, 978–984[Abstract/Free Full Text]
  26. Kanakaraj, P., Ngo, K., Wu, Y., Angulo, A., Ghazal, P., Harris, C. A., Siekierka, J. J., Peterson, P. A., and Fung-Leung, W. P. (1999) J. Exp. Med. 189, 1129–1138[Abstract/Free Full Text]
  27. Li, X., Commane, M., Burns, C., Vithalani, K., Cao, Z., and Stark, G. R. (1999) Mol. Cell. Biol. 19, 4643–4652[Abstract/Free Full Text]
  28. Wesche, H., Gao, X., Li, X., Kirschning, C. J., Stark, G. R., and Cao, Z. (1999) J. Biol. Chem. 274, 19403–19410[Abstract/Free Full Text]
  29. Kobayashi, K., Hernandez, L. D., Galan, J. E., Janeway, C. A., Jr., Medzhitov, R., and Flavell, R. A. (2002) Cell 110, 191–202[Medline] [Order article via Infotrieve]
  30. Li, S., Strelow, A., Fontana, E. J., and Wesche, H. (2002) Proc. Natl. Acad. Sci. U. S. A. 99, 5567–5572[Abstract/Free Full Text]
  31. Cao, Z., Henzel, S. J., and Gao, X. (1996) Science 271, 1128–1131[Abstract]
  32. Suzuki, N., Suzuki, S., Duncan, G. S., Millar, D. G., Wada, T., Mirtsos, C., Takada, H., Wakeham, A., Itie, A., Li, S., Penninger, J. M., Wesche, H., Ohashi, P. S., Mak, T. W., and Yeh, W. C. (2002) Nature 416, 750–756[CrossRef][Medline] [Order article via Infotrieve]
  33. Sambrook, J., Fritch, E. F., and Maniatis, T. (1989) Molecular Cloning: A Laboratory Manual, 2nd Ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
  34. Ye, H., Arron, J. R., Lamothe, B., Cirilli, M., Kobayashi, T., Shevde, N. K., Segal, D., Dzivenu, O. K., Vologodskaia, M., Yim, M., Du, K., Singh, S., Pike, J. W., Darnay, B. G., Choi, Y., and Wu, H. (2002) Nature 418, 443–447[CrossRef][Medline] [Order article via Infotrieve]